The growing number of infectious diseases is expected to drive the growth of the Indian streptomycin market during the forecast period.
According to TechSci Research report, “India Streptomycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India streptomycin market is expected to grow at a steady rate during the forecast period. World Health Organization has included streptomycin in the list of essential medicines that are safe and most effective medicines required in the healthcare system. Streptomycin is used to treat a number of diseases such as tuberculosis, meningitis, throat Infection and so on. This is expected to fuel the market growth through FY2026. Furthermore, rising use of antibiotics in cell culture is further projected to bode well for the market growth in the next 5 years. However, patent expiration and availability of substitute products are some of the impediments that can restrict the market growth over the next few years. Moreover, increasing resistance to antibiotics is another major concern that might further reduce the application of the drug thereby hindering the market growth during the forecast period. For instance, according to the Centers for Disease Control and Prevention, it is estimated that around 2 million illnesses and 23,000 deaths occur due to antibiotic resistance every year.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Streptomycin Market”
The Indian streptomycin market is segmented based on source, form, route of administration, type of manufacturing process, distribution channel, application, end-user, company, and region. Based on end-user, the market can be fragmented into adult v/s pediatric. The adult segment is forecasted to dominate the market during the forecast period. This dominance can be accredited to the wide use of streptomycin in adults to treat a number of infectious diseases. Based on the source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until FY2020 as most of the leading companies focus on in-house production owing to high standardization and flexibility. Contract manufacturing organizations segment is expected to witness high growth in the market as it saves cost and maximizes profits.
Macleods Pharmaceuticals Ltd., Abbott Healthcare Pvt Ltd. (AHPL), Hindustan Antibiotics Ltd. (HAL), Nestor Pharmaceuticals Ltd., Nitin Lifesciences Ltd., Wockhardt Limited, Neon Laboratories Ltd., Shalina Laboratories Pvt. Ltd., Wellona Pharma Pvt. Ltd., Cipla Ltd., and others are some of the leading players operating in India streptomycin market. Companies operating in the market are using strategies such as product launches, mergers and acquisitions, and research collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7200
Customers can also request for 10% free customization on this report.
“India’s streptomycin market is expected to witness growth during the forecast period owing to the rising use of antibiotics in cell culture. In addition to this, increasing awareness by various government and non-government organizations to control the bacterial infectious disease among people is further expected to create lucrative opportunities for the market growth of the Indian streptomycin market in the forthcoming years. A growing number of antibiotic manufacturers coupled with the presence of some of leading generics manufacturers in the country are some other major factors that are projected to bolster the market growth in the next 5 years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based India management consulting firm.
“India Streptomycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India streptomycin market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the Indian streptomycin market.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Copyright © 2014 - 2021 The Global Indian New Network (TGINN)